Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0242706 (
hyperoxia
)
5,219
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Oxidative stress has both detrimental and beneficial effects. Kallistatin, a key component of circulation, protects against vascular and organ injury. Serum
kallistatin
levels are reduced in patients and animal models with hypertension, diabetes, obesity, and cancer. Reduction of
kallistatin
levels is inversely associated with elevated thiobarbituric acid-reactive substance. Kallistatin therapy attenuates oxidative stress and increases endothelial nitric oxide synthase (eNOS) and NO levels in animal models. However,
kallistatin
administration increases reactive oxygen species formation in immune cells and bacterial killing activity in septic mice. High oxygen inhibits
kallistatin
expression via activating the JNK-FOXO1 pathway in endothelial cells. Conversely, mild oxygen/
hyperoxia
stimulates
kallistatin
, eNOS, and hypoxia-inducible factor-1 (HIF-1) expression in endothelial cells and in the kidney of normal mice. Likewise,
kallistatin
stimulates eNOS and HIF-1, and
kallistatin
antisense RNA abolishes oxygen-induced eNOS and HIF-1 expression, indicating a role of
kallistatin
in mediating mild oxygen's stimulation on antioxidant genes. Protein kinase C (PKC) activation mediates HIF-1-induced eNOS synthesis in response to
hyperoxia
/exercise; thus, mild oxygen through PKC activation stimulates
kallistatin
-mediated HIF-1 and eNOS synthesis. In summary, oxidative stress induces down- or upregulation of
kallistatin
expression, depending on oxygen concentration, and
kallistatin
plays a novel role in mediating oxygen/exercise-induced HIF-1-eNOS-NO pathway.
...
PMID:Opposing Effects of Oxygen Regulation on Kallistatin Expression: Kallistatin as a Novel Mediator of Oxygen-Induced HIF-1-eNOS-NO Pathway. 2938 92